Allocentric Spatial Memory Testing Predicts Conversion from Mild Cognitive Impairment to Dementia: An Initial Proof-of-Concept Study by Wood, RA et al.
December 2016 | Volume 7 | Article 2151
Original research
published: 01 December 2016
doi: 10.3389/fneur.2016.00215
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Stefano L. Sensi, 
University of California, Irvine, USA
Reviewed by: 
Valerio Frazzini, 
G. d’Annunzio University, Italy 
Nicola Mammarella, 
University of Chieti-Pescara, Italy 
Giorgia Committeri, 
University of Chieti-Pescara, Italy
*Correspondence:
Dennis Chan 
dc598@medschl.cam.ac.uk
Specialty section: 
This article was submitted to 
Neurodegeneration, 
a section of the journal 
Frontiers in Neurology
Received: 05 September 2016
Accepted: 15 November 2016
Published: 01 December 2016
Citation: 
Wood RA, Moodley KK, Lever C, 
Minati L and Chan D (2016) 
Allocentric Spatial Memory Testing 
Predicts Conversion from Mild 
Cognitive Impairment to Dementia: 
An Initial Proof-of-Concept Study. 
Front. Neurol. 7:215. 
doi: 10.3389/fneur.2016.00215
allocentric spatial Memory Testing 
Predicts conversion from Mild 
cognitive impairment to Dementia: 
an initial Proof-of-concept study
Ruth A. Wood1,2, Kuven K. Moodley1, Colin Lever 3, Ludovico Minati4,5 and Dennis Chan6*
1 Department of Medicine, Brighton and Sussex Medical School, Falmer, UK, 2 Sainsbury Wellcome Centre for Neural Circuits 
and Behaviour, University College London, London, UK, 3 Department of Psychology, University of Durham, Durham, UK, 
4 U.O. Direzione Scientifica, Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy, 5 Centro Interdipartimentale 
Mente/Cervello (CIMeC), Università di Trento, Trento, Italy, 6 Department of Clinical Neurosciences, University of Cambridge, 
Cambridge, UK
The hippocampus is one of the first regions to exhibit neurodegeneration in Alzheimer’s 
disease (AD), and knowledge of its role in allocentric spatial memory may therefore aid 
early diagnosis of AD. The 4 Mountains Test (4MT) is a short and easily administered 
test of spatial memory based on the cognitive map theory of hippocampal function as 
derived from rodent single cell and behavioral studies. The 4MT has been shown in pre-
vious cross-sectional studies to be sensitive and specific for mild cognitive impairment 
(MCI) due to AD. This report describes the initial results of a longitudinal study testing 
the hypothesis that allocentric spatial memory is predictive of conversion from MCI to 
dementia. Fifteen patients with MCI underwent baseline testing on the 4MT in addition 
to CSF amyloid/tau biomarker studies, volumetric MRI and neuropsychological assess-
ment including the Rey Auditory Verbal Learning Test (RAVLT) and Trail Making Test “B” 
(TMT-B). At 24 months, 9/15 patients had converted to AD dementia. The 4MT predicted 
conversion to AD with 93% accuracy (Cohen’s d = 2.52). The predictive accuracies of 
the comparator measures were as follows: CSF tau/β-amyloid1–42 ratio 92% (d = 1.81), 
RAVLT 64% (d = 0.41), TMT-B 78% (d = 1.56), and hippocampal volume 77% (d = 0.65). 
CSF tau levels were strongly negatively correlated with 4MT scores (r = −0.71). This 
proof-of-concept study provides initial support for the hypothesis that allocentric spatial 
memory testing is a predictive cognitive marker of hippocampal neurodegeneration in 
pre-dementia AD. The 4MT is a brief, non-invasive, straightforward spatial memory test 
and is therefore ideally suited for use in routine clinical diagnostic practice. This is of 
particular importance given the current unmet need for simple accurate diagnostic tests 
for early AD and the ongoing development of potential disease-modifying therapeutic 
agents, which may be more efficacious when given earlier in the disease course. By 
applying a test based on studies of hippocampal function in rodents to patient popula-
tions, this work represents the first step in the development of translatable biomarkers of 
hippocampal involvement in early AD for use in both animal models and human subjects.
Keywords: alzheimer’s disease, mild cognitive impairment, spatial memory, hippocampus, Four Mountains Test, 
dementia
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inTrODUcTiOn
The anticipated arrival of disease-modifying drugs for the treat-
ment of Alzheimer’s disease (AD) places increased emphasis 
on the need to identify AD in its earliest stages, when such 
treatments may have greatest benefit in delaying or preventing 
the onset of dementia. It is now accepted that AD presents as 
mild cognitive impairment (MCI) in its prodromal stages (1), 
but MCI can also be caused by non-AD disorders with lower 
dementia risk, including non-neurodegenerative conditions such 
as anxiety. Identification of MCI on clinical grounds alone cannot 
discriminate between the various differing underlying etiologies 
(2, 3). The high prevalence of memory impairment in the aging 
population [in a US study, 27% of people over 65 years reported 
memory decline (4)] amplifies the difficulty of accurately differ-
entiating MCI due to AD and highlights the need for diagnostic 
tests that are not only sensitive and specific for pre-dementia AD 
but are also non-invasive and usable in routine clinical diagnostic 
practice.
This need is not met by current tests. Screening tests of global 
cognitive function of the kind typically used in primary care, such 
as the Mini-Mental State Examination (MMSE), have low diag-
nostic specificity and are poor predictors of conversion to demen-
tia (5, 6). Tests of specific cognitive domains, such as episodic 
memory or attention, have higher diagnostic accuracy but require 
training in administration and scoring and are primarily used 
in specialist clinics (7–9). Biomarker-based tests, such as MRI 
measurements of hippocampal atrophy, amyloid-PET scanning, 
or CSF studies of amyloid/tau, have higher predictive accuracy 
(10–12), but the high cost, limited availability, and invasive nature 
of some tests preclude their usage in routine clinical practice.
This need may be met by a hippocampus-dependent test 
of allocentric spatial memory. Neuropathological studies have 
shown the hippocampus to be one of the first brain regions 
affected in AD (13), and there is extensive evidence that the 
hippocampus is critically involved in spatial memory, with the 
demonstration in rodents of spatially related firing activity of 
hippocampal neurons “place cells” (14) and of a correlation 
between place cell activity and spatial memory (15). Importantly, 
in an open arena, hippocampal spatial neurons signal location in 
an allocentric reference frame. Place cells and boundary cells fire 
in a viewpoint-independent manner such that a given neuron 
fires at broadly similar rates whether the subject is, for instance, 
facing north or south as it moves through the neuron’s locational 
firing field (16, 17). This signaling of viewpoint-independent 
location is a defining characteristic of hippocampal spatial 
representation.
A role for the human hippocampus in spatial memory is sup-
ported by pre-surgical depth electrode recordings of place-related 
firing of hippocampal neurons (18), and functional imaging 
studies showing activation of the hippocampus during spatial 
memory tasks (19, 20). Patients with focal hippocampal lesions 
show disproportionate impairment of spatial memory (21), and 
several studies have shown that spatial memory is impaired in 
patients with MCI and AD (22–25). However, to date, the ability 
of spatial memory testing to predict conversion from MCI to AD 
dementia has not been evaluated.
A variety of differing behavioral paradigms have been used to 
test spatial memory in humans. These include the Hidden Goal 
Task (26), which was designed as a human analog of the Morris 
water maze used for rodent studies (27) and assesses memory 
for hidden locations within a three meter diameter, circular, 
velvet arena, as well as a variety of tests of spatial navigation and 
memory using desktop-based virtual reality (VR) paradigms 
(22, 28). However, these paradigms have operational limitations 
that render them unsuitable for use as diagnostic tests for pro-
dromal AD in routine clinical practice. The space requirements 
of the Hidden Goal Task effectively precludes its usage beyond 
research labs with dedicated testing arenas, whereas the various 
VR tests used to date require significant tester input and have 
been associated with nausea and disorientation when applied to 
older individuals with early AD (29).
The 4 Mountains Test (4MT) is an easily administered test 
of allocentric spatial memory, which builds upon the defining 
characteristic of hippocampal spatial representation mentioned 
above in discussing rodent spatial neurons: the signaling of 
viewpoint-independent location. Essentially, the task requires 
that the participant correctly identifies a previously seen location, 
though the viewpoint the location is seen from has shifted from 
sample to test. The 4MT is specifically designed to be resistant 
to non-spatial strategies (30). The 4MT can be applied in paper 
form, with or as an iPad app, and requires little in the way of tester 
training or instructions (a video example of test administration 
is viewable via the open access article by Chan et al. (31)). The 
brevity of the test (around 10 minutes for the paper version and 
around 8 minutes for the app) is comparable to the MMSE (Mini 
Mental State Examination Test) (5), which is widely used world-
wide as a short screening test for cognitive impairment but a poor 
predictor of progression from MCI to dementia (6). Following 
the initial use of this test to demonstrate that patients with 
focal hippocampal damage were selectively impaired on spatial 
memory testing, with relative preservation of spatial perception 
and non-spatial memory (30), performance on the 4MT has been 
found to discriminate between AD and non-AD dementia (29, 
32) and between MCI patients with and without CSF biomarker 
evidence of underlying AD (33).
Following on from these cross-sectional studies, this initial 
longitudinal study used the 4MT to test the primary hypothesis 
that allocentric spatial memory test performance is predictive 
of conversion from MCI to AD dementia. Additionally, the 
secondary hypothesis that spatial memory is a behavioral marker 
of hippocampal neurodegeneration in early AD was tested by 
correlating 4MT scores with levels of CSF total tau, representing 
a biomarker of neurodegeneration in AD.
MaTerials anD MeThODs
subjects
Fifteen patients with multiple domain MCI, all of whom presented 
with memory impairment, were recruited from the Cognitive 
Disorders Clinic, Hurstwood Park Neurological Centre, 
Haywards Heath, West Sussex, and from the East Sussex Memory 
Assessment Service. The baseline cross-sectional data on 13/15 
TaBle 1 | Demographic variables and candidate predictors of conversion.
Demographic or predictor variable Mci – converters 
(mean ± se)
Mci – non-converters 
(mean ± se)
Difference  
statistic
p-value* cohen’s d  
(effect size)
Gender 2 F:7 M 2 F:4 M X21 = 0.227 0.63 –
Age 71.7 ± 3.0 65.2 ± 3.4 T13 = 1.41 0.18 0.75
Years of education 12.1 ± 0.7 11.0 ± 0.5 T13 = 1.19 0.26 0.67
NART estimated IQ 106.6 ± 3.9 114.7 ± 3.4 T10 = 1.50 0.16 0.90
4MT score 5.56 ± 0.71 10.17 ± 0.60 T13 = 4.60 0.0005 2.52
TMT-B (s) 132.55 ± 14.98 80.78 ± 8.36 T12 = 2.74 0.018 1.56
RAVLT score 2.38 ± 0.62 3.33 ± 0.14 T12 = 0.79 0.45 0.41
MMSE score 27.89 ± 0.42 27.33 ± 0.21 T13 = 1.01 0.33 0.58
Total hippocampal volume (% of total intracranial volume) 0.509 ± 0.037 0.577 ± 0.45 T11 = 1.18 0.26 0.65
CSF total tau:β-amyloid1–42 3.57 ± 0.92 0.45 ± 0.09 T11 = 3.12 0.001 1.81
MCI, mild cognitive impairment; 4MT, Four Mountains Test; TMT-B, Trail Making Test B; RAVLT, Rey Auditory Verbal Learning Test; MMSE, Mini Mental State Examination.
*Uncorrected p-values.
Bold font signifies p-values that are statistically significant at the p < 0.05 level.
FigUre 1 | The 4 Mountains Test. (a) A landscape containing four 
mountains is presented for 8 seconds and then removed. (B) After a 2 second 
delay, this landscape is re-presented, but from a rotated viewpoint, with three 
additional “foil” landscapes, in a delayed match-to-sample paradigm (the 
correct response is the bottom right image).
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MCI patients have been reported by Moodley et al. (33), and all 
baseline data are summarized in Table 1. MCI was diagnosed by a 
neurologist (Kuven K. Moodley and Dennis Chan) in accordance 
with the Petersen criteria (34). Initial screening blood tests were 
undertaken to exclude reversible causes of cognitive impairment, 
such as vitamin B12 deficiency and thyroid dysfunction. Subjects 
were excluded from the study if they had depression, other psy-
chiatric diagnoses, a significant vascular lesion load on MRI and/
or a Hachinski Ischemic Score >4 (35). The degree and extent 
of objective cognitive impairment was established at baseline in 
clinic using the Addenbrooke’s Cognitive Examination – Revised 
(36), which includes the MMSE (5), or the Queen Square 
Screening Test for Cognitive Deficits (©EK Warrington, 2003) 
plus the MMSE.
As part of their diagnostic work-up 13/15 MCI subjects had 
CSF tested for AD biomarkers (CSF β-amyloid1–42, CSF tau, CSF 
tau/β-amyloid1–42 ratio) using industry standard ELISA assay kits 
(Innotest, Innogenetics, Ghent, Belgium) in accordance with the 
CSF collection protocol of the CSF sub-study of the Alzheimer’s 
disease Neuroimaging Initiative (ADNI) (37). The 13/15 subjects 
had MRI scans with T1-weighted volumetric MRI data acquired 
on a 1.5T Siemens Avanto scanner based at the Clinical Imaging 
Sciences Centre, Brighton and Sussex Medical School using 
a magnetization-prepared rapid-acquisition gradient-echo 
sequence to generate voxels of 1  mm ×  1  mm ×  1  mm. Total 
hippocampal volumes, corrected for total intracranial volume, 
were measured using the FSL(version 5.0)/FIRST tool (FMRIB, 
Oxford Centre for Functional Magnetic Resonance Imaging of 
the Brain, Oxford, UK) (38). In those instances where CSF and 
MRI investigations were not undertaken, this was due to patient 
preference.
The study was undertaken in accordance with the Declaration 
of Helsinki and all participants provided written informed con-
sent. Ethical approval was obtained from the UK Research Ethics 
Committee South East Coast – Brighton and Sussex (references 
10/H1107/23 and 13/LO/0277).
The 4 Mountains Test
A full description of the 4MT is provided by Hartley et  al. 
(30). The spatial memory test involves presentation of 
computer-generated landscapes, each containing images of four 
mountains arranged around the center of the landscape, in the 
form of printed color images within an A4-sized booklet. For 
each test item, a sample image is presented for eight seconds. 
After a two second delay, this image is re-presented, but from 
a different viewpoint, alongside three foil images of landscapes 
with differing topography (Figure  1). Fifteen test items were 
shown in all, and the total test duration was approximately ten 
minutes. Participants completed the 4MT alongside additional 
neuropsychological tests at entry into the study, with all testing 
undertaken during a single sitting.
Baseline neuropsychological Testing
Subjects completed a battery of baseline neuropsychological tests, 
which included the National Adult Reading Test (NART) (39) 
to obtain an estimation of premorbid IQ in line with numer-
ous other studies of cognitive function in clinical cohorts, and 
subtests of the Visual Object and Space Perception battery (40) 
for assessment of visual perception. The neuropsychological test 
battery also included two tests considered to be sensitive to early 
AD (1) and thus effective predictors of progression from MCI to 
AD dementia (8, 41). These are the Rey Auditory Verbal Learning 
Test [RAVLT; (42)], a test of episodic memory, and the Trail 
Making Test “B” (TMT-B) (43), a test probing several cognitive 
domains including attention, speed of information processing, 
and executive function. One subject declined to complete the 
tests outlined above due to anxiety.
TaBle 2 | Binary classification using candidate predictor variables.
criterion for 
positive test  
(see methods)
Prevalence  
(of converter positive 
cases in sample, %)
sensitivity  
(%)
specificity 
(%)
PPV:nPV 
(%)
accuracy  
(%)
Youden’s J aUc ± se aUc p-value  
(0.5 aUc = H0)
4MT score ≤8 60 (n = 15) 100 83.3 90.0:100 93.3 0.833 0.981 ± 0.022 <0.0001
TMT-B (s) >102.6 57.1 (n = 14) 62.5 100 100:66.7 78.6 0.625 0.875 ± 0.094 0.0001
RAVLT score ≤3 57.1 (n = 14) 75.0 50.0 66.7:60.0 64.3 0.250 0.604 ± 0.168 0.54
MMSE score ≤27 60 (n = 15) 44.4 33.3 50.0:28.6 40.0 −0.222 0.370 ± 0.140 >0.5*
Total hippocampal 
volume (% of TIV)
≤0.570 53.8 (n = 13) 85.7 66.7 75.0:80.0 76.9 0.524 0.714 ± 0.163 0.19
CSF total 
tau:β-amyloid1–42
>0.821 53.8 (n = 13) 85.7 100 100:85.7 92.3 0.857 0.905 ± 0.100 0.0001
PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve; TIV, total intracranial volume.
*An exact p-value is not given here as the ROC curve for MMSE was below the chance line.
Bold font signifies p-values that are statistically significant at the p < 0.05 level.
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Determination of conversion status
Conversion status was determined 24 months after study enroll-
ment by a neurologist (Kuven K. Moodley and Dennis Chan) in 
clinic, blinded to the baseline 4MT score, with the diagnosis of 
AD dementia made in accordance with the 2011 McKhann cri-
teria (44). In addition to the presence of cognitive or behavioral 
symptoms involving at least two cognitive domains, conversion 
to AD dementia from MCI was based on decline in cognitive 
function on objective testing, new impairment in activities of 
daily living and loss of functional independence, represent-
ing changes from the time of the previously attributed MCI 
diagnosis.
comparison of 4MT Performance with 
Other Measures
The ability of the 4MT to predict conversion from MCI to demen-
tia was compared with five other measures. In addition to the 
RAVLT (delayed free recall score) and TMT-B (completion time), 
comparisons were made with the MMSE score, total hippocampal 
volume, and CSF tau/β-amyloid1–42 ratio.
The rationale for these additional comparisons is as follows. 
While systematic reviews have shown that the predictive ability 
of the MMSE is low (6), it is part of the Preclinical Alzheimer 
Cognitive Composite (45) that is approved by the FDA for use 
as an outcome measure in trials of treatments aiming to delay 
progression from MCI to dementia. Furthermore, the MMSE is 
used widely as a cognitive screening test in UK memory services, 
notably in primary care, and as such the MMSE score has a bear-
ing on the clinical management of patients presenting with MCI. 
Total hippocampal volume and CSF tau/β-amyloid1–42 ratio are 
included as comparators in view of their status as AD biomarkers 
included within research criteria for the diagnosis of MCI due 
to AD (1).
These five comparator measures were analyzed as both con-
tinuous (Table 1) and binary (Table 2) variables.
statistical analysis
Data were analyzed using MedCalc Statistical Software version 
15.6.1 (MedCalc Software bvba, Ostend, Belgium, 2015). For all 
continuous data, normality was assessed using normal probability 
plots and Shapiro–Wilk testing, and Levene’s test was applied to 
ensure homogeneity of variances. No corrections were necessary. 
Cohen’s d provided a measure of effect size, calculated by divid-
ing the difference between the group means by their pooled SD 
(√[(StDevConverters2 + StDevNon-Converters2)/2]).
The threshold criteria for binary classification (MCI con-
verters vs. MCI non-converters) for each of the comparators 
were selected by maximizing Youden’s index J (Table 2), where 
Youden’s J = sensitivity + specificity − 1. The SE of the area under 
the curve (AUC) and the probability value of the AUC under the 
null hypothesis of AUC = 0.5 were calculated according to the 
method of DeLong et al. (46).
resUlTs
Demographics
There were no statistically significant differences between 
MCI converters and MCI non-converters in terms of age 
[71.7 ±  3.0  years (mean ±  SE) vs. 65.2 ±  3.4, p =  0.18], years 
of education (12.1 ± 0.7 vs. 11.0 ± 0.5, p = 0.26), gender (2 F:7 
M vs. 2 F:4 M, p = 0.634), or NART estimated IQ (106.6 ± 3.9 
vs. 114.7 ±  3.4, p =  0.16). An ANCOVA of the 4MT score vs. 
converter status, with age and IQ as covariates, showed that 
their effect on conversion status was non-significant (p = 0.223, 
p = 0.332, respectively). The effect of 4MT score on conversion 
status remained significant even after accounting for group dif-
ferences in age and IQ.
correlation of 4MT score with  
csF aD Biomarkers
4MT scores were strongly negatively correlated with the levels 
of CSF total tau (r = −0.71, p = 0.007; Figure 2F) but did not 
correlate with the levels of CSF Aβ1–42 (r = 0.5, p = 0.08). CSF tau 
levels were negatively correlated with total hippocampal volume 
(r = −0.59, p = 0.04) in keeping with previous studies (47, 48), but 
after controlling for hippocampal volume, CSF tau still robustly 
predicted 4MT spatial memory score (n = 12, partial r = −0.84, 
p = 0.001).
Thirteen subjects were available for the 4MT vs. hippocampal 
volume correlation. An r value ≥0.56 would be required for 
FigUre 2 | (a–e) Threshold plots illustrating the differences in scores/measures between converters and non-converters. (a) 4 Mountains Test (4MT) spatial 
memory score, (B) Trail Making Test B (TMT-B) time (s), (c) Rey Auditory Verbal Learning Test (RAVLT) score (Delayed Free Recall), (D) total hippocampal volume (as 
% of total intracranial volume), and (e) CSF tau:β-amyloid1–42. (F) Scatterplot illustrating the relationship between CSF total tau and 4MT score. Gray dashed line 
indicates line of best fit.
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significance in a two-tailed test where n =  13. The correlation 
coefficient obtained in this sample, r =  0.43, is therefore not 
statistically significant. However, it is worth noting that this value 
is similar to that observed in a much larger sample of MCI and 
AD patients (33).
accuracy of 4MT and comparator 
Variables in Predicting conversion to 
Dementia
At 24-month follow-up, 9/15 MCI patients converted to AD 
dementia, with the remaining 6/15 patients having unchanged 
diagnoses of MCI. MCI converter and non-converter groups 
differed significantly on 4MT (lower scores in converters, 
p = 0.0005, Cohen’s d = 2.52), TMT-B (longer completion time 
in converters, p = 0.018, Cohen’s d = 1.56), and in terms of CSF 
tau/β-amyloid1–42 ratios (lower ratios in converters, p =  0.001, 
Cohen’s d = 1.81) (Table 1; Figures 2A,B,E). The two groups did 
not differ significantly in terms of MMSE score, RAVLT delayed 
free recall score or total hippocampal volume (all p-values ≥ 0.33, 
Table 1; Figures 2C,D). ROC curve analysis for the study predic-
tor variables showed that the AUC was significantly above chance 
for 4MT score (AUC = 0.981, p < 0.0001), CSF tau/β-amyloid1–42 
ratio (AUC = 0.905, p = 0.0001), and TMT-B time (AUC = 0.875, 
p =  0.0001) (Table  2). MMSE, RAVLT, and total hippocampal 
volume did not predict conversion (all p-values ≥ 0.19, Table 2; 
Figures 2C,D).
Only two measures were associated with overall classification 
accuracies and Youden’s J values above 80%, namely the 4MT 
score (93%, 0.833) and CSF tau/β-amyloid1–42 ratios (93%, 0.857) 
(Table 2; Figures 2A,E).
DiscUssiOn
Spatial memory is impaired in patients with mild dementia due 
to AD (24, 25, 32, 49), and more recent work has demonstrated 
that impairment is already evident in the pre-dementia stages 
of AD (33, 50). Both allocentric and egocentric spatial memory 
have been observed to be defective in patients with amnestic MCI 
(22–25), with some evidence that allocentric spatial memory, 
dependent on hippocampal function, is more impaired in these 
patients than egocentric spatial memory, which is more depend-
ent on striatal function (51).
No studies to date have demonstrated that performance on 
a spatial memory task can predict conversion from MCI to AD 
dementia. Given the prevalence of memory impairment in the 
aging population and the difficulty of distinguishing MCI due to 
AD from other causes of memory impairment (such as depres-
sion or anxiety) on clinical grounds alone, the identification of 
6Wood et al. Spatial Memory Testing Predicts AD
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a test with high predictive value would have major benefits for 
clinical practice on a large scale.
The 4 Mountains Test (4MT) of allocentric spatial memory has 
been shown in a previous cross-sectional study to differentiate 
MCI due to AD (32, 33). This initial longitudinal study of 15 MCI 
patients followed up over 24 months provides early support for the 
hypothesis that allocentric spatial memory testing is an accurate 
predictor of conversion from MCI to AD dementia. Performance 
on the 4MT predicted conversion with a classification accuracy 
of 93%, superior to the predictive accuracy of cognitive tests 
widely used in clinical and research practice for the diagnosis of 
MCI, with a 64% accuracy observed with the RAVLT and a 79% 
accuracy associated with the TMT-B. Given its widespread usage 
in clinical practice worldwide, a comparison was also made with 
the MMSE, and the low predictive accuracy (40%) associated 
with this test in the current study is consistent with the findings of 
a recent systematic review (6), which concluded that the MMSE 
was a poor predictor of conversion.
Further comparison with the predictive accuracy of AD 
biomarkers was undertaken. Total hippocampal volume, widely 
used as an outcome measure in treatment trials aimed at delay-
ing the progression from MCI to AD dementia, was associated 
with an accuracy of 77%. The 92% predictive accuracy of the 
CSF tau/β-amyloid1–42 ratio is similar to the 93% accuracy of the 
4MT, while the positive and negative predictive values of the CSF 
tau/β-amyloid1–42 ratio of 100 and 86%, respectively, bear com-
parison with figures of 81 and 96% from a previous longitudinal 
study (52).
CSF total tau, considered to be a measure of tau release 
from dying or dysfunctional neurons containing neurofibril-
lary tangles, is used as a biomarker of neurodegeneration in 
AD and levels of CSF total tau are negatively correlated with 
performance on the RAVLT and semantic fluency tests (47, 53). 
While correlations are also observed with hippocampal volume 
(47), this is the first study to report a correlation between CSF 
total tau and performance on a hippocampus-dependent spatial 
memory task. The strength of the correlation (r = −0.71) sug-
gests that testing of allocentric spatial memory may represent 
a behavioral marker of tau-related hippocampal neurodegen-
eration. This has increased significance in light of the current 
practice of using β-amyloid biomarkers for diagnosing AD in 
its pre-dementia stages or as screening tests for clinical trials, 
in the form of CSF β-amyloid1–42 or amyloid-PET scanning. 
The recent observation that a third of cognitively healthy 
older individuals with positive CSF amyloid biomarkers did 
not exhibit any cognitive decline over 9-year follow-up (54) 
illustrates the limitations associated with β-amyloid biomark-
ers and the importance of markers of neurodegeneration in 
predicting cognitive decline in individuals at risk of developing 
dementia.
In addition to the above, these initial findings have further 
implications for experimental medicine and clinical practice. 
First of all, the successful application to clinical diagnostic 
practice of a test based on a theory of hippocampal function 
derived from single cell and behavioral studies in rodents (55) 
helps bridge the divide between basic and clinical neuroscience 
and represents a significant step forward in the development of 
translatable behavioral markers of early AD. Second, the brief 
duration of the 4MT, combined with its ease of application and 
scoring, ensures that this test is ideally suited for use as a diagnos-
tic test for pre-dementia AD not only in specialist clinics but also 
in non-specialist diagnostic practice, such as primary care clinics 
and community-based memory assessment services. These 
typically represent the first points of medical contact for people 
with memory decline and the potential value of the 4MT in this 
context is underscored by the observation in this study (and oth-
ers) that the MMSE, which is the cognitive test most widely used 
in non-specialist clinics, is a poor predictor of conversion from 
MCI to dementia.
The usability and potential for widespread clinical applica-
tion of the 4MT differentiates this test from other behavioral 
tests of spatial memory. Alternative tests of allocentric spatial 
memory, such as the virtual radial maze task (28, 49), the 
Hidden Goal Task (23) and the Virtual Route Learning Test 
(29), are based on the same underlying theoretical principles 
as the 4MT and accordingly have identified spatial behavioral 
deficits in patients with MCI. However, the complexity of test 
administration (especially with older adults) and problems with 
tolerability (e.g., nausea experienced during testing) limits the 
utility of these tasks in routine diagnostic practice. To date, the 
accuracy of these tasks for predicting conversion from MCI to 
AD has not been evaluated, and further studies comparing their 
prognostic value with that of the 4MT would be of considerable 
interest.
Several further issues are raised by this initial work. One 
is that of the incremental added value of the 4MT, above and 
beyond that of “traditional” cognitive tests. The comparisons 
with the RAVLT and TMT-B outlined above and in our previous 
cross-sectional study (33) show a superior diagnostic sensitivity 
of the 4MT for prodromal AD and a greater predictive ability, 
and therefore provide first evidence of added prognostic value. 
These data justify further investigation of this critical issue by 
application of logistic regression statistical methodologies within 
currently running large sample size studies.
In this study a 30% annual conversion rate from MCI to 
dementia was observed which exceeds the 20% annual conver-
sion rate previously reported for MCI with positive CSF AD 
biomarkers (52). This may reflect the recruitment from a tertiary 
referral memory clinic, typically associated with higher conver-
sion rates than community-based populations, but may also be a 
consequence of the small sample size.
It is crucial to reiterate the point that these are preliminary 
observations. While these findings are sufficient to provide initial 
proof of concept, the small sample size does not permit any defini-
tive conclusions to be drawn. Furthermore, only relatively strong 
correlations can be detected with this sample size. For instance, 
while a strong correlation between 4MT score and CSF total tau 
was identified, the presence of a correlation between 4MT score 
and hippocampal volume will need to be established in a larger 
sample.
Nonetheless, this initial dataset has been considered suf-
ficiently robust for the 4MT to be included in the test battery 
used to evaluate cognitive function in prospective, large scale 
longitudinal studies of the older population at risk of developing 
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dementia, namely the n =  750 PREVENT study (56) and the 
n =  6000 EPAD (European Prevention of Alzheimer’s Disease, 
http://ep-ad.org) initiative. These studies of asymptomatic at-risk 
individuals will be complemented by further longitudinal studies 
of MCI patients whose aims are to determine the predictive accu-
racy of the 4MT in larger cohorts drawn from community- and 
hospital-based memory clinics as well as the specificity of this test 
in determining future conversion to AD and non-AD dementia.
cOnclUsiOn
This study provides the first evidence supporting the hypothesis 
that testing of allocentric spatial memory is predictive of conver-
sion from MCI to AD dementia. The correlation between CSF 
total tau and 4MT score indicates that the latter may represent a 
behavioral marker of hippocampal neurodegeneration. The brev-
ity, non-invasiveness and ease of application of the 4MT means 
that this test is capable of fulfilling the current unmet need for an 
accurate test of pre-dementia AD that can be scaled up to address 
the high diagnostic demand associated with the prevalence of 
memory impairment in the aging population.
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